Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Buldini

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Journal of Hematology & Oncology|April 21, 2026
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013Franco Locatelli, Barbara Buldini, Martina Pigazzi, et al.
Haematologica|May 15, 2012
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemiaGiuseppe Gaipa, Giovanni Cazzaniga, Maria Grazia Valsecchi, et al.
Blood|October 24, 2018
Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemiaAlice Bertaina, Marco Zecca, Barbara Buldini, et al.
The Lancet. Haematology|February 9, 2016
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysisValentino Conter, Maria Grazia Valsecchi, Barbara Buldini, et al.
Haematologica|February 27, 2025
<i>Ex vivo</i> drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with <i>PICALM::MLLT10</i>Elena Mastrodicasa, Luca Pagliaro, Valentina Pierini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary TrialsElizabeth A Raetz, Paola Rebora, Valentino Conter, et al.
Hemasphere|June 12, 2023
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic LeukemiaChiara Palmi, Silvia Bresolin, Stefanie Junk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2023
Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 TrialMyriam Campbell, Csongor Kiss, Martin Zimmermann, et al.
Blood|July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 studyMartin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Journal of Hematology & Oncology|April 21, 2026
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013Franco Locatelli, Barbara Buldini, Martina Pigazzi, et al.
Haematologica|May 15, 2012
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemiaGiuseppe Gaipa, Giovanni Cazzaniga, Maria Grazia Valsecchi, et al.
Blood|October 24, 2018
Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemiaAlice Bertaina, Marco Zecca, Barbara Buldini, et al.
The Lancet. Haematology|February 9, 2016
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysisValentino Conter, Maria Grazia Valsecchi, Barbara Buldini, et al.
Haematologica|February 27, 2025
<i>Ex vivo</i> drug response profiling guides therapy in a case of high-risk acute undifferentiated leukemia with <i>PICALM::MLLT10</i>Elena Mastrodicasa, Luca Pagliaro, Valentina Pierini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary TrialsElizabeth A Raetz, Paola Rebora, Valentino Conter, et al.
Hemasphere|June 12, 2023
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic LeukemiaChiara Palmi, Silvia Bresolin, Stefanie Junk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2023
Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 TrialMyriam Campbell, Csongor Kiss, Martin Zimmermann, et al.
Blood|July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 studyMartin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Pageof 9